# Boyi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boyi

- Industry: Biotechnology
- Headquarters: Changzhou, China
- Website: www.boyibiotech.com
- Total disclosed funding: $14M
- Latest round: Series A (Aug 9, 2024)
- Investors on record: 4

## About

Based in Changzhou, China, and founded in 2022, Boyi is a biotech company providing in vitro diagnostic material for biomedical customers. In May 2023, Boyi raised more than CNY 100 million in series A funding led by new investor Jolmo Capital, with participation from other new investors Changzhou Weichi Equity Fund Management, Coastal Capital, and Guoping Hua, founder of Hualan. In Augusr 2024, the firm closed a series A+ funding.

The company's business can be categorized into diagnostic microspheres, assay raw materials, customized services, and large package reagents, which include latex microspheres, colored microspheres, fluorescent microspheres, antigens, antibodies, enzymes, and other raw materials for IVD assays.

The company’s revenue is generated by providing in vitro diagnostic core raw materials.

## Funding rounds

- Series A, Aug 9, 2024 — Green Pine Capital Partners
- Series A, May 30, 2023, $14M — Coastal Capital, Jolmo Capital, Changzhou Weichi Equity Fund Management

## Investors

- Coastal Capital (https://capitalatlas.ai/funds/coastal-capital) — Series A
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A
- Changzhou Weichi Equity Fund Management — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A